193 related articles for article (PubMed ID: 15927253)
1. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
[TBL] [Abstract][Full Text] [Related]
2. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
3. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
4. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
[TBL] [Abstract][Full Text] [Related]
5. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
[TBL] [Abstract][Full Text] [Related]
6. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
Liu Z; Liu XL; Du QF; Xu N; Zhong M; Song LL; Yi ZS; Liu QF; Meng FY; Zhou SY
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):512-5. PubMed ID: 19304540
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
[TBL] [Abstract][Full Text] [Related]
10. [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
Parovichnikova EN; Savchenko VG; Verniuk MA; Vinogradova OA; Misiurin AV; Vorob'ev IA; Domracheva EV; Tikhonova LIu; Rukavitsyn OA; Rossiev VA; Kliasova GA; Turkina AG; Liubimova LS; Mendeleeva LP; Isaev VG
Ter Arkh; 2005; 77(7):11-6. PubMed ID: 16116902
[TBL] [Abstract][Full Text] [Related]
11. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A
J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084
[TBL] [Abstract][Full Text] [Related]
13. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
Storring JM; Minden MD; Kao S; Gupta V; Schuh AC; Schimmer AD; Yee KW; Kamel-Reid S; Chang H; Lipton JH; Messner HA; Xu W; Brandwein JM
Br J Haematol; 2009 Jun; 146(1):76-85. PubMed ID: 19438471
[TBL] [Abstract][Full Text] [Related]
14. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
15. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
17. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
Zhou L; Hu J; Chen J; Du S; Wang A; You J; Wu W; Shen Z; Li J
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):109-13. PubMed ID: 24606650
[TBL] [Abstract][Full Text] [Related]
19. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
[TBL] [Abstract][Full Text] [Related]
20. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
